-
Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
05 Feb 2025 07:15 GMT
… plus docetaxel versus docetaxel alone (docetaxel subgroup population … TTFields therapy plus docetaxel, docetaxel alone, TTFields … therapy + docetaxel versus docetaxel alone docetaxel alone.
Discussion … docetaxel in previously treated non-small-cell lung cancer …
-
Datopotamab Deruxtecan Granted Priority Review in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
13 Jan 2025 07:07 GMT
… antibody drug conjugate for lung cancer, providing a promising … of datopotamab deruxtecan versus docetaxel in adult patients … breast cancer, small cell lung cancer, urothelial, gastric, pancreatic, … Small Cell Lung Cancer
Nearly 2.5 million lung cancer cases …
-
AstraZeneca, Daiichi Sankyo withdraw EU application for lung cancer treatment
26 Dec 2024 19:29 GMT
… advanced nonsquamous non-small cell lung cancer (NSCLC).
Dato-DXd is intended … safety of the asset against docetaxel in adults with advanced or … progression-free survival (PFS) over docetaxel.
Despite the promising data, the …
-
New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
05 Feb 2025 22:00 GMT
… adenocarcinoma or non–small cell lung cancer (NSCLC) that are … or non–small cell lung cancer (NSCLC) that are … of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter … docetaxel for second-line treatment of stage IV non-small-cell lung cancer …
-
Publication du New England Journal of Medicine : Efficacité du zénocutuzumab dans le cancer positif à la fusion NRG1
05 Feb 2025 22:00 GMT
… therapy of NRG1 fusion-driven lung cancers: the eNRGy1 global multicenter registry … al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment … of stage IV non-small-cell lung cancer …
-
„New England Journal of Medicine“ veröffentlicht: Wirksamkeit von Zenocutuzumab bei NRG1-fusionspositivem Krebs
05 Feb 2025 22:00 GMT
… NRG1 fusion-driven lung cancers: the eNRGy1 global … plus docetaxel versus placebo plus docetaxel for … second-line treatment of stage IV non-small-cell lung cancer … Ramucirumab plus Docetaxel versus Placebo plus Docetaxel zur Zweitlinienbehandlung …
-
Repurposed Drug Shows Promise for Lung Cancer
10 Dec 2024 10:42 GMT
… a major subset of lung cancer patients.
“This novel … Society. About 85% of lung cancer patients have the NSCLC … treatments for KRAS mutant lung cancer remain a major unmet … docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer …
-
Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
09 Dec 2024 12:13 GMT
… small cell lung cancer
Nearly 2.5 million lung cancer cases were … of datopotamab deruxtecan versus docetaxel in adult patients with … improvements for people with lung cancer, including and beyond treatment … in non-small cell lung cancers and its correlation with …
-
Datopotamab Deruxtecan Granted Breakthrough Therapy Designation in U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
09 Dec 2024 07:20 GMT
… of datopotamab deruxtecan versus docetaxel in adult patients with … 2024 World Conference on Lung Cancer hosted by the International … for the Study of Lung Cancer (#WCLC24) and simultaneously … Small Cell Lung Cancer
Nearly 2.5 million lung cancer cases were …
-
Datopotamab Deruxtecan Demonstrated Meaningful Clinical Activity in Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer in TROPION-Lung05 and TROPION-Lung01 Pooled Analysis
06 Dec 2024 02:27 GMT
… mutated non-small cell lung cancer with disease progression … deruxtecan in later-line lung cancer settings.”
Patients in … of datopotamab deruxtecan versus docetaxel in adult patients with … Small Cell Lung Cancer
Nearly 2.5 million lung cancer cases were …
About
© 1995-2025